BSE filing, NSE: BACPHAR. Summary written from the filing by ALFA Finder's alert engine.
Bacil Pharma Ltd: key numbers
- Share price
- ₹19.36
- Market cap
- ₹27.79 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹1.56 Cr
- P/E (TTM)
- 44.0×Sector 46.1×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bacil Pharma Ltd
All →Bacil Pharma Other Announcement
Bacil Pharma Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.
Bacil Pharma Q2 FY27 Results: Net Loss of ₹0.1 Cr
Bacil Pharma Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.1 Cr
Bacil Pharma Management Change
Mr. Dikshant Singh Panwar has resigned as Whole-Time Company Secretary and Compliance Officer of Bacil Pharma Limited, effective October 8, 2026.
Bacil Pharma Board Meeting Date
Bacil Pharma will hold a board meeting on October 14, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.
Bacil Pharma Annual Report
Bacil Pharma Limited submitted its 39th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for September 23, 2026, via video conferencing.
Bacil Pharma Annual General Meeting
Bacil Pharma Limited has announced book closure dates from September 17 to September 23, 2026, for its 39th Annual General Meeting.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr